Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells $67,663.20 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOKGet Free Report) General Counsel Jonathan Allan sold 5,126 shares of the company’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $13.20, for a total transaction of $67,663.20. Following the completion of the transaction, the general counsel now directly owns 2,598 shares of the company’s stock, valued at $34,293.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Jonathan Allan also recently made the following trade(s):

  • On Tuesday, March 19th, Jonathan Allan sold 2,349 shares of Stoke Therapeutics stock. The stock was sold at an average price of $6.10, for a total transaction of $14,328.90.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $13.08 on Wednesday. The firm’s 50-day moving average is $6.58 and its 200-day moving average is $5.19. The stock has a market cap of $605.60 million, a price-to-earnings ratio of -5.52 and a beta of 0.76. Stoke Therapeutics, Inc. has a 52-week low of $3.35 and a 52-week high of $16.40.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on STOK. TD Cowen upgraded shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. Canaccord Genuity Group increased their price objective on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Needham & Company LLC increased their price objective on shares of Stoke Therapeutics from $14.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Wedbush upped their target price on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. Finally, JPMorgan Chase & Co. upped their target price on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a report on Tuesday, March 26th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Stoke Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $19.63.

View Our Latest Report on STOK

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Stoke Therapeutics by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 1,648,502 shares of the company’s stock valued at $8,671,000 after acquiring an additional 17,814 shares during the period. Barclays PLC raised its holdings in Stoke Therapeutics by 365.3% in the 4th quarter. Barclays PLC now owns 39,271 shares of the company’s stock valued at $206,000 after acquiring an additional 30,831 shares during the period. Granahan Investment Management LLC raised its holdings in Stoke Therapeutics by 33.7% in the 4th quarter. Granahan Investment Management LLC now owns 1,137,887 shares of the company’s stock valued at $5,985,000 after acquiring an additional 286,686 shares during the period. Bridgeway Capital Management LLC bought a new position in Stoke Therapeutics in the 4th quarter valued at about $90,000. Finally, Birchview Capital LP raised its holdings in Stoke Therapeutics by 147.1% in the 4th quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock valued at $1,105,000 after acquiring an additional 125,000 shares during the period.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Featured Articles

Insider Buying and Selling by Quarter for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.